Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson's operational sales growth reached 11.5% in the fourth quarter of 2025, even after considering a significant competitive headwind from generics on Stelara. The company's total revenue estimate for 2026 has been raised to $100.42 billion, supported by strong performances from key products like Tremfya and Rybrevant, indicating robust growth prospects. With impressive stock performance and a favorable outlook following 4Q results, JNJ demonstrates strong fundamentals poised for continued upward momentum.

Bears say

Johnson & Johnson faces significant risks that contribute to a negative outlook for its stock, particularly relating to the potential for rapid sales declines following the loss of patent exclusivity for key products, which could allow generics and biosimilars to capture market share. Disappointing launches of new medications, concerns surrounding macroeconomic factors such as U.S. drug pricing reform, and litigation risks associated with ongoing talc-related lawsuits could further pressure sales and earnings forecasts. Additionally, the failure of crucial pipeline assets, including posdinemab, amplifies uncertainty regarding future revenue streams, leading to heightened volatility in the company’s stock performance.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $234.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $234.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.